Precigen Inc (PGEN) Stock Price, Quote & News

Company Profile

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell t...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 556 9900

Website: precigen.com

Address:

20374 Seneca Meadows Parkway, Germantown, United States

forgottenchuck May. 15 at 7:21 PM

$PGEN just bought more

0 · Reply

Amb8675309 May. 15 at 6:58 PM

$PGEN this one gets bought out it’s gonna be the SOC. Having all these people go in multiple times a year get sedated and then hack all these warts out of their throat that just doesn’t math long-term patience on this one. Buy on dips

0 · Reply

Vic1931 May. 15 at 6:24 PM

$PGEN No worries. Actually make July/August calls cheaper and this one is about patience. Great report but no "J code" effect factored in yet. Report factored just a full quater of papzimeos. Now the next one will have a full jcode factored in since it started 4/1. Plus Fridays usually a "meh" market day. Just hold.

1 · Reply

Ottonagy May. 15 at 2:12 PM

$PGEN with that great earnings report they had this should be at least at $6.50 and it should be able to hold those prices and slowly should go even somewhere around $8 per share

0 · Reply

Ottonagy May. 15 at 2:10 PM

$PGEN this is pathetic unbelievable the company had such a great earnings report that they never had before and here we go we are going down. We are going back to the price we were at before this great earnings report makes absolutely no sense.

2 · Reply

StockDad0927 May. 15 at 1:47 PM

$PGEN 🖕🏻 all sellers

0 · Reply

dsup May. 14 at 8:02 PM

$PGEN does it end the OE week above 4.5. can’t believe this thing didn’t even test 5 today. crazy how much it’s being held down

3 · Reply

iBio_GlaisterPIT May. 14 at 7:35 PM

$PGEN Some good work here! Worth looking at…

0 · Reply

Vic1931 May. 14 at 7:29 PM

$SLS STFU Biobiiiiish. You've been demoted to pink-slip junk tickers. Your "Mayor" campaign derailed by your own pie hole. Have some decency and move to another stock. Move to $PGEN where you will get humiliated again. 🤷‍♂️🤘

3 · Reply

forgottenchuck May. 14 at 6:40 PM

$PGEN

0 · Reply

Precigen price target raised to $11 from $10 at H.C. Wainwright

2026-05-14T09:56:27.000Z - 1 day ago

Precigen price target raised to $11 from $9 at Citizens

2026-05-13T21:07:28.000Z - 1 day ago

Precigen reports Q1 EPS (2c) vs. (18c) last year

May 13, 2026, 4:30 PM EDT - 1 day ago

Precigen Earnings Call Transcript: Q1 2026

May 13, 2026, 4:05 PM EDT - 2 days ago

Precigen Reports First Quarter 2026 Financial Results and Business Updates

May 7, 2026, 4:05 PM EDT - 8 days ago

Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13

2026-04-07T12:02:54.000Z - 5 weeks ago

Precigen sees Q1 revenue exceeding $18M, consensus $20.8M

2026-04-07T11:17:44.000Z - 5 weeks ago

Precigen sees ‘robust uptake’ in usage of Papzimeos since its launch

Apr 7, 2026, 7:00 AM EDT - 5 weeks ago

Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million

Mar 31, 2026, 11:00 AM EDT - 6 weeks ago

Precigen Transcript: Fireside chat

Mar 30, 2026, 8:30 AM EDT - 6 weeks ago

Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31

2026-03-26T15:25:13.000Z - 7 weeks ago

Precigen jumps on Q1 outlook despite earnings miss

2026-03-26T10:10:56.000Z - 7 weeks ago

Precigen price target raised to $10 from $9 at H.C. Wainwright

2026-03-26T10:00:46.000Z - 7 weeks ago

Precigen price target raised to $9 from $8 at Citizens

Mar 25, 2026, 4:30 PM EDT - 7 weeks ago

Precigen Earnings Call Transcript: Q4 2025

Mar 25, 2026, 4:05 PM EDT - 7 weeks ago

Precigen Reports Full Year 2025 Financial Results and Business Updates

2026-03-25T12:05:16.000Z - 7 weeks ago

Options Volatility and Implied Earnings Moves Today, March 25, 2026

BYND BZUN CHWY CTAS JEF KC PAYX

Mar 11, 2026, 4:05 PM EDT - 2 months ago

Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25

Jan 20, 2026, 8:05 AM EST - 4 months ago

New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis

Jan 15, 2026, 10:30 AM EST - 4 months ago

Precigen Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:00 AM EST - 4 months ago

Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:05 PM EST - 4 months ago

Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-03T15:00:13.000Z - 5 months ago

JPMorgan healthcare analysts hold an analyst/industry conference call

2025-11-14T11:16:04.000Z - 6 months ago

Precigen price target raised to $9 from $8.50 at H.C. Wainwright

2025-11-13T21:31:56.000Z - 6 months ago

Precigen reports Q3 EPS ($1.06) vs. (9c) last year

Nov 13, 2025, 4:30 PM EST - 6 months ago

Precigen Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:05 PM EST - 6 months ago

Precigen Reports Third Quarter 2025 Financial Results and Business Updates

Nov 6, 2025, 4:30 PM EST - 6 months ago

Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13

2025-10-13T11:05:34.000Z - 7 months ago

Precigen presents long-term data demonstrating durable responses to PAPZIMEOS

Oct 13, 2025, 7:00 AM EDT - 7 months ago

Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis

Sep 3, 2025, 7:00 AM EDT - 9 months ago

Precigen Announces Up to $125 Million Non-Dilutive Financing

Sep 2, 2025, 11:00 AM EDT - 9 months ago

Precigen Transcript: Fireside Chat

Aug 25, 2025, 8:05 AM EDT - 9 months ago

Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

2025-08-19T21:35:16.000Z - 9 months ago

Precigen files to sell 143.81M shares of common stock for holders

2025-08-19T09:40:13.000Z - 9 months ago

Precigen price target raised to $8 from $6 at Citizens JMP

2025-08-18T13:40:19.000Z - 9 months ago

Unusually active option classes on open August 18th

AG BBAI FSLR IQ NVAX NVO PCG

Aug 18, 2025, 8:00 AM EDT - 9 months ago

Precigen Transcript: Investor Update

Aug 15, 2025, 7:18 AM EDT - 9 months ago

US FDA approves Precigen's immunotherapy for rare respiratory disease

Aug 15, 2025, 7:00 AM EDT - 9 months ago

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

May 14, 2025, 4:05 PM EDT - 1 year ago

Precigen Reports First Quarter 2025 Financial Results and Business Updates

Apr 16, 2025, 8:05 AM EDT - 1 year ago

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

Mar 19, 2025, 4:30 PM EDT - 1 year ago

Precigen Earnings Call Transcript: Q4 2024

Mar 19, 2025, 4:05 PM EDT - 1 year ago

Precigen Reports Full Year 2024 Financial Results and Business Updates

Mar 13, 2025, 8:05 AM EDT - 1 year ago

Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

Feb 25, 2025, 8:05 AM EST - 1 year ago

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Jan 16, 2025, 12:00 PM EST - 1 year ago

Precigen Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 7:00 AM EST - 1 year ago

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:30 AM EST - 1 year ago

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 30, 2024, 7:00 AM EST - 1 year ago

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Dec 27, 2024, 9:00 AM EST - 1 year ago

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Nov 19, 2024, 10:55 AM EST - 1 year ago

Precigen Transcript: Stifel 2024 Healthcare Conference

Nov 14, 2024, 4:30 PM EST - 1 year ago

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Nov 12, 2024, 4:05 PM EST - 1 year ago

Precigen to Participate in the Stifel 2024 Healthcare Conference

Sep 16, 2024, 4:30 PM EDT - 1 year ago

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Precigen Earnings Call Transcript: Q2 2024

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

Aug 7, 2024, 9:30 PM EDT - 1 year ago

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock

Aug 6, 2024, 4:04 PM EDT - 1 year ago

Precigen Announces Proposed $30 Million Public Offering of Common Stock

Aug 6, 2024, 4:01 PM EDT - 1 year ago

Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch

Jul 23, 2024, 8:01 AM EDT - 1 year ago

Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

Jun 3, 2024, 7:00 PM EDT - 2 years ago

Precigen Transcript: Study Result

Jun 3, 2024, 9:30 AM EDT - 2 years ago

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

May 23, 2024, 5:00 PM EDT - 2 years ago

Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

May 14, 2024, 4:05 PM EDT - 2 years ago

Precigen Reports First Quarter 2024 Financial Results and Business Updates

May 8, 2024, 4:05 PM EDT - 2 years ago

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

Apr 24, 2024, 10:20 AM EDT - 2 years ago

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

Apr 24, 2024, 9:00 AM EDT - 2 years ago

Actym Therapeutics Appoints Thomas Smart as CEO

ANAB XOMA

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

Mar 19, 2024, 4:30 PM EDT - 2 years ago

Precigen Earnings Call Transcript: Q4 2023

Mar 19, 2024, 4:05 PM EDT - 2 years ago

Precigen Reports Full Year 2023 Financial Results and Business Updates

Mar 12, 2024, 4:05 PM EDT - 2 years ago

Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Mar 5, 2024, 4:05 PM EST - 2 years ago

Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th

Feb 13, 2024, 3:20 PM EST - 2 years ago

Precigen Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference (Virtual)

Feb 6, 2024, 4:05 PM EST - 2 years ago

Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 16, 2024, 8:05 AM EST - 2 years ago

Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Jan 10, 2024, 8:15 PM EST - 2 years ago

Precigen Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 8, 2024, 8:30 AM EST - 2 years ago

Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 18, 2023, 4:05 PM EST - 2 years ago

Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 6, 2023, 3:00 PM EST - 2 years ago

Precigen Transcript: The JMP Securities Hematology and Oncology Summit

Nov 29, 2023, 4:05 PM EST - 2 years ago

Precigen to Participate in the JMP Securities Hematology and Oncology Summit

Nov 15, 2023, 10:55 AM EST - 2 years ago

Precigen Transcript: Stifel 2023 Annual Healthcare Conference

Nov 9, 2023, 4:55 PM EST - 2 years ago

Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs

forgottenchuck May. 15 at 7:21 PM

$PGEN just bought more

0 · Reply

Amb8675309 May. 15 at 6:58 PM

0 · Reply

Vic1931 May. 15 at 6:24 PM

1 · Reply

Ottonagy May. 15 at 2:12 PM

$PGEN with that great earnings report they had this should be at least at $6.50 and it should be able to hold those prices and slowly should go even somewhere around $8 per share

0 · Reply

Ottonagy May. 15 at 2:10 PM

2 · Reply

StockDad0927 May. 15 at 1:47 PM

$PGEN 🖕🏻 all sellers

0 · Reply

dsup May. 14 at 8:02 PM

$PGEN does it end the OE week above 4.5. can’t believe this thing didn’t even test 5 today. crazy how much it’s being held down

3 · Reply

iBio_GlaisterPIT May. 14 at 7:35 PM

$PGEN Some good work here! Worth looking at…

0 · Reply

Vic1931 May. 14 at 7:29 PM

3 · Reply

forgottenchuck May. 14 at 6:40 PM

$PGEN

0 · Reply

M22 May. 14 at 5:27 PM

$PGEN 😂😂🤑🤑🤑🤑😂😂

0 · Reply

StockDad0927 May. 14 at 4:49 PM

$PGEN @rubraquercus you still here? Your negative energy is missed.

3 · Reply

StockDad0927 May. 14 at 4:47 PM

$PGEN will never understand how people can sell this stock.

0 · Reply

chungana May. 14 at 3:42 PM

$PGEN Buyout would have to be between $13-15 per share, imho…More the longer potential suitors wait…🧐

1 · Reply

chungana May. 14 at 2:54 PM

$PGEN July 17 expiry: 15,000+ $3 Puts??? 🤯

0 · Reply

chungana May. 14 at 2:50 PM

$PGEN Hope they fry tomorrow, if they haven’t gotten out yet…🔥🔥🔥

0 · Reply

Gimme_a_like May. 14 at 2:14 PM

$PGEN Rise and Shine!

0 · Reply

chungana May. 14 at 2:03 PM

$PGEN Could be smart ones exiting positions while they can during this artificial price manipulation…Some may be foolishly pressing their luck until expiry… 🤔

1 · Reply

Elliotwavedave May. 14 at 1:52 PM

$PGEN tomorrow

0 · Reply

chungana May. 14 at 1:21 PM

$PGEN Still a lot if fake shares being printed…Recall options expiry tomorrow—a lot of crooks underwater if this closes above $4.50 tomorrow; so, you can see the crooks are very busy trying to cover their dumba&&es.

2 · Reply

RayD73 May. 14 at 1:19 PM

$PGEN Don't be fooled by this pre-market retreat. BUY!!!!

0 · Reply

iBio_GlaisterPIT May. 14 at 1:06 PM

$PGEN I’ve mentioned several times over the last year or more how Papzimeos is really just the tiny tip of their iceberg. The real value is in the larger platform. Others agree: https://stocktwits.com/news-articles/markets/equity/why-pgen-stock-is-rising-today-precigen-papzimeos-analyst-upgrade/cZX189kRe1L

0 · Reply

Market Cap	1.48B
Revenue (ttm)	9.68M
Net Income (ttm)	-250.64M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	204.00
Profit Margin	-2,589.26%
Debt to Equity Ratio	4.46

Volume	2,810,530
Avg Vol	4,192,268
Day's Range	N/A - N/A
Shares Out	356.51M
Stochastic %K	68%
Beta	1.07
Analysts	Sell
Price Target	$9.50